DCTH Delcath Systems Inc

Price (delayed)

$21.39

Market cap

$744.12M

P/E Ratio

118.83

Dividend/share

N/A

EPS

$0.18

Enterprise value

$690.99M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 81

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) ...

Highlights
The price to earnings (P/E) is 75% lower than the last 4 quarters average of 484.5
Delcath Systems's gross profit has increased by 40% YoY and by 16% from the previous quarter
Delcath Systems's debt has surged by 150% YoY but it has decreased by 2.2% QoQ
DCTH's quick ratio is down by 25% year-on-year but it is up by 14% since the previous quarter

Key stats

What are the main financial stats of DCTH

DCTH stock price

How has the Delcath Systems stock price performed over time
Intraday
-1.75%
1 week
47.62%
1 month
36.5%
1 year
149.01%
YTD
111.78%
QTD
33.94%

Financial performance

How have Delcath Systems's revenue and profit performed over time
Revenue
$109.96M
Gross profit
$96.31M
Operating income
$5.6M
Net income
$6.65M
Gross margin
87.6%
Net margin
6.1%
Delcath Systems's gross profit has increased by 40% YoY and by 16% from the previous quarter
The company's revenue rose by 38% YoY and by 15% QoQ
DCTH's operating margin is down by 30% year-on-year
The operating income has declined by 3.2% year-on-year

Price vs fundamentals

How does DCTH's price correlate with its fundamentals

Growth

What is Delcath Systems's growth rate over time

Valuation

What is Delcath Systems stock price valuation
P/E
118.83
P/B
5.56
P/S
7.02
EV/EBIT
63.12
EV/EBITDA
59.79
EV/Sales
6.28
The price to earnings (P/E) is 75% lower than the last 4 quarters average of 484.5
DCTH's P/B is 62% higher than its last 4 quarters average of 3.5
Delcath Systems's equity has increased by 16% YoY and by 10% from the previous quarter
The price to sales (P/S) is 59% more than the last 4 quarters average of 4.5 but 49% less than the 5-year quarterly average of 13.9
The company's revenue rose by 38% YoY and by 15% QoQ

Efficiency

How efficient is Delcath Systems business performance
Delcath Systems's ROS has soared by 186% from the previous quarter

Dividends

What is DCTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DCTH.

Financial health

How did Delcath Systems financials performed over time
DCTH's total liabilities has surged by 65% year-on-year but it is down by 2% since the previous quarter
Delcath Systems's current ratio has decreased by 28% YoY but it has increased by 11% from the previous quarter
Delcath Systems's debt is 98% lower than its equity
Delcath Systems's debt has surged by 150% YoY but it has decreased by 2.2% QoQ
DCTH's debt to equity has soared by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.